carboplatin

(redirected from Paraplatin)
Also found in: Medical.

carboplatin

[¦kär·bō′plat·ən]
(medicine)
A platinum coordination compound and anticancer agent used for advanced gynecologic malignancies, especially ovarian tumors, and for head and neck cancers and lung cancers.
References in periodicals archive ?
Lucidi was also worldwide vice president Virology & Oncology at Johnson & Johnson, where he led portfolio strategy from drug discovery to market and served in senior leadership at Bristol-Myers Squibb, where he was responsible for the strategy and launch of several new antiviral and oncology products, includingVidex (didanosine), Zerit (stavudine), Paraplatin (carboplatin) andTaxol (paclitaxel).
He was worldwide vice-president virology & oncology at Johnson & Johnson where he led portfolio strategy from drug discovery to market, and served in senior leadership at Bristol-Myers Squibb where he was responsible for the strategy and launch of several new antiviral and oncology products, including but not limited to Videx (didanosine), Zerit (stavudine), Paraplatin (carboplatin) and Taxol (paclitaxel).
Chemotherapy treatment commonly centers on platinum drugs, such as cisplatin (Platinol[R]) and paraplatin (Carboplatin[R]).
The other drugs reviewed that also had no new safety concerns were anti-neoplastic agent Camptosar (irinotecan), antineoplastic agent Paraplatin (carboplatin), platelet-reducing agent Agrylin (anagrelide), and hematinic agent Ferrlecit (sodium ferric gluconate complex).
patent in 2005: * Diflucan * Aredia * Engerix-B * Combivir * Lovenox * Lamisil * Lupron * Paxil * Paraplatin * Pravachol * Procrit * Prevacid * Wellbutrin SR/Zyban * Zithromax * Xenical * Zocor * Zofran * Zoladex * Zoloft Sources: NDC Health and Generic Pharmaceutical Association (Information as of January 2003)
Known for its development of innovative treatments of hypertension, heart disease, stroke, diabetes and HIV/AIDS drugs, the company is the number one provider worldwide of chemotherapeutic agents such as Taxol, Ifex and Paraplatin.
Bristol-Myers Squibb--whose oncology operation rests on such in-licensed drugs as Paraplatin, Platinol, and Taxol--derives more than 95 percent of its oncology revenues from in-licensed products.
The product is the generic version of Bristol-Myers Squibb's Paraplatin Injection.
Those products include Taxol and Paraplatin, anticancer drugs; Glucophage and Glucovance, diabetes treatments; and Pravachol, a cholesterol agent.
M2 EQUITYBITES-June 10, 2014-Mylan unveils US FDA approved generic Paraplatin Injection for advanced ovarian carcinoma
M2 PHARMA-June 10, 2014-Mylan unveils US FDA approved generic Paraplatin Injection for advanced ovarian carcinoma
The patent expires of major branded products, such as Taxol (paclitaxel), Paraplatin (carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of generics, have acted as restraining factors to the market.